Sanguine Bioscience, a California-based biotechnology company focused on patient recruitment, sample collection engagement and digital health, has partnered with multiple biotech and pharmaceutical companies, such as Vir Biotechnology and EpiVax, Inc, to facilitate the patient recruitment for over 23 research studies, studies aimed at gaining a better understanding of COVID-19.
As a chronic autoimmune disease, patients with systemic lupus erythematosus (SLE) experience widespread inflammation and unpredictable disease flare episodes that progressively worsen over time, contributing to tissue and organ damage. Its heterogeneous nature, slow disease progression, and seemingly random symptom flares complicate research studies aimed at improving therapeutic options for SLE patients.
Certain disease studies exploring sensitive biomarkers or molecules with a short half-life require blood analysis soon after collection to prevent important blood components from breaking down, which may have a negative effect on study results. Numerous factors such as diet, medications, supplements, and patient hydration can affect blood test results.
The largest barrier to conducting clinical research is the high cost. According to the Tufts Center for the Study of Drug Development (CSDD), it now costs up to $2.6 billion to bring a new drug to market, up from $1 billion from the 1990s to the early 2000s, and costs are continuing to rise.
Rheumatoid arthritis (RA) is an autoimmune disorder characterized by joint swelling, pain, and damage from chronic inflammation. RA occurs in roughly 5 per 1,000 people and may cause severe and irreversible joint damage and debilitation1. The key to combating RA is early diagnosis and treatment with various anti-inflammatory agents collectively known as disease-modifying antirheumatic drugs (DMARDs), which can prevent or slow joint damage in 90% of patients.
Hepatitis B virus (HBV) is the world’s most common cause of chronic viral infection. Individuals may become infected through contact with bodily fluids or from mother to child during birth. Some people with acute HBV infections experience symptoms like vomiting, yellowish skin, dark urine, fatigue, and abdominal pain, while others feel no symptoms at all.
People with Duchenne muscular dystrophy (DMD) suffer from a range of muscular issues, including a loss of motor, pulmonary, and cardiac functions, which eventually leads to death. Early signs of the disease include developmental delays, enlarged calf muscles, a waddling gait, generalized muscle weakness, and difficulty performing physical activities.
Biobanks store various biological samples for research use. Although they have become an important resource for researchers since their introduction in the late 1990s, biobanks provide limited samples and associated information. Sanguine sought to overcome challenges commonly encountered with biobanks by creating a universal protocol for delivering quality standardized biospecimens to the biomedical research community.
The broad spectrum of clinical manifestations seen in systemic lupus erythematosus (SLE) makes it challenging to characterize the disease meaningfully. Particularly problematic for researchers and physicians alike is the apparent classification of differences between acute episodes and chronic disease damage. To that end, the SLE disease activity index (SLEDAI-2K) functions to standardize the assessment of disease severity by clinicians globally.
Crohn’s disease (CD) is on the rise. A form of inflammatory bowel disease affecting the gastrointestinal (GI) tract, CD causes abdominal pain, diarrhea, fever, and weight loss. Complications like bowel obstruction may occur, and those afflicted with CD have a higher risk of bowel cancer..